Erratum in: “A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice”, by Arenas MD et al, J Nephrol 2010; 23(6): 683-692

Arenas, María Dolores; Rebollo, Pablo; Malek, T; Moledous, A; Gil, Teresa; Álvarez-Ude, F; Morales, Ana; Cotilla, E

doi:10.5301/jn.2012.9136

Cited by 10 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Optimizing regimen with alternative PBs has been found effective in previous studies. The daily pill burden from PB was reduced to half after changing from SH to LC, and the adherence rate increased from 46.9% at baseline to 72.5% at 12 months, with a significant decrease in the treatment cost incurred from PB [25] .…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Medication Regimen Complexity and Adherence in Haemodialysis Patients: An Exploratory Study

et al. 2016

View full text Add to dashboard Cite

Background: The impact of medication regimen complexity on adherence in hemodialysis patients is unknown. We investigated regimen complexity, perceived burden of medicines (PBM) and health-related quality of life (HR-QoL) as potential predictors of adherence. Methods: Adult (≥18 years) hemodialysis patients were included. Data on medication regimen complexity index (MRCI), self-reported and objective adherence, comorbidity index, PBM and HR-QoL were obtained using established measures. Sociodemographic and clinical characteristics were collected during interviews and by reviewing medical records. Predictors of adherence were determined using logistic regression. Results: Fifty-three out of 70 hemodialysis patients participated (response rate 75%; male 58.5%; age 67.9 ± 11.5 years). The mean MRCI, HR-QoL and PBM scores were 27.0 ± 10.9, 0.70 ± 0.13 and 1.7 ± 0.6, respectively. Based on self-reports, 43.4% (n = 23) were adherent, whereas for a subset of patients analyzed using objective measure (n = 33), much lower adherence rate was observed (27.3%, n = 9). The self-reported and objective measures were significantly correlated (r = 0.43, p = 0.01). Older age was the only significant predictor of self-reported adherence (OR 1.05; 95% CI 1.00-1.11) whereas older age (OR 1.10; 95% CI 1.00-1.21), higher comorbidity (OR 1.58; 95% CI 1.03-2.42) and MRCI (OR 1.14; 95% CI 1.02-1.27) were independent predictors of objective adherence. Conclusions: The findings of this exploratory study suggest that older patients with high comorbidities and highly complex regimen are more likely to be adherent based on an objective measure. Future research is needed using objective measures of adherence suitable for all patients and reflecting all medications.

show abstract

Section: Discussionmentioning

confidence: 92%

“…Lower rates of adherence to PBs have been linked with the type of binders prescribed [25] . More than two-thirds of the patients prescribed with PB were taking SH in our sample.…”

Section: Discussionmentioning

confidence: 99%

Medication Regimen Complexity and Adherence in Haemodialysis Patients: An Exploratory Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…As such, its use is not expected to contribute to tissue and vascular calcification, and could have beneficial effects on cardiovascular morbidity and mortality 11 . In a recent study, reductions in pill burden and cost were shown with lanthanum use when compared with sevelamer 12 . This resulted in an improvement in patient compliance to lanthanum.…”

Section: Discussionmentioning

confidence: 99%

“…11 In a recent study, reductions in pill burden and cost were shown with lanthanum use when compared with sevelamer. 12 This resulted in an improvement in patient compliance to lanthanum. The efficacy of crushed lanthanum in binding P after a dietary P load has been demonstrated in healthy volunteers in a single-dose study.…”

Section: Discussionmentioning

confidence: 99%

Phosphate‐binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients

How¹,

Anattiwong²,

Mason³

et al. 2010

Hemodialysis International

View full text Add to dashboard Cite

Lanthanum carbonate, a chewable noncalcium-containing phosphorus (P) binder, is useful for treating secondary hyperparathyroidism in patients who have hypercalcemia and cannot swallow whole tablets. However, some patients cannot chew tablets or prefer to crush and mix them with food. This study was conducted to determine the P-binding efficacy of crushed lanthanum and compare it with chewed lanthanum in hemodialysis (HD) patients. After a 1-week washout period, 11 hemodialysis patients (7 men, 4 women) were randomized to receive, in a crossover fashion, lanthanum 1000 mg 3 times daily chewed with meals and lanthanum 1000 mg 3 times daily crushed into a fine powder, mixed with applesauce and taken with meals, for 4 weeks each. Serum P was measured at the end of each washout (baseline) and weekly during treatment. Changes in serum P from baseline for crushed lanthanum were compared with chewed lanthanum using paired sample t test. Administration of crushed lanthanum resulted in a significant reduction in serum P from baseline (P reduction [mg/dL] for crushed lanthanum in week 1: 2.1 ± 0.4, week 2: 1.7 ± 0.5, week 3: 1.7 ± 0.5, week 4: 1.7 ± 0.4, P<0.05). No statistically significant differences were observed in serum P reduction from baseline and serum P attained during treatment with crushed when compared with chewed lanthanum. Crushed lanthanum is effective in reducing serum P and have similar P-binding efficacy to chewed lanthanum. Crushing lanthanum and mixing it with food can thus be an option for patients who are unable to chew or swallow whole tablets.

show abstract

“…LC is especially widely used because it seems to have no effect on serum calcium levels as compared with calcium‐based phosphate binders . It also has high binding potential to phosphorus, is cost‐effective compared with sevelamer, and is useful for patients who either have hypercalcemia or cannot swallow tablets. In Japan, LC was initially released in a chewable tablet form.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients

Sakurada

Oishi

Shibagaki

et al. 2013

Hemodialysis International

View full text Add to dashboard Cite

Lanthanum carbonate (LC) has been administered in a chewable tablet form for patients with hyperphosphatemia undergoing dialysis. However, some patients have difficulty chewing the tablets. LC oral powder has recently been released in Japan. The purpose of this study was to clarify the efficacy of LC oral powder form compared with that of chewable tablet form. The efficacy and safety of LC oral powder was retrospectively assessed in hemodialysis patients who switched from chewable tablet form to oral powder form without dose modification. Thirty-six patients (mean age, 66.8 ± 10.5 years; male, 64%; 39% with diabetes; mean duration of dialysis treatment, 99.2 ± 95.6 months) were enrolled in this study between June and July of 2012. Changes in clinical data and adverse events after the switch to oral powder form were investigated. The average dose of LC was 1180 ± 520 mg/day. Serum phosphorus levels were significantly decreased after the switch from chewable tablet form to oral powder form (5.3 ± 1.7 mg/dL at baseline vs. 4.9 ± 1.2 mg/dL at after 1 month after, P = 0.038). In contrast, no significant differences were observed in serum calcium and parathyroid hormone levels. Furthermore, no significant differences were evident in weight gain after the switch to oral powder form (2.5 ± 1.2 kg at baseline vs. 2.4 ± 1.1 kg at 1 month after the switch, P = 0.29). No serious adverse events were recorded. Our results suggest that LC is more effective in oral powder form than chewable tablet form for hemodialysis patients.

show abstract

Erratum in: “A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice”, by Arenas MD et al, J Nephrol 2010; 23(6): 683-692

Cited by 10 publications

References 0 publications

Medication Regimen Complexity and Adherence in Haemodialysis Patients: An Exploratory Study

Medication Regimen Complexity and Adherence in Haemodialysis Patients: An Exploratory Study

Phosphate‐binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients

Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients

Contact Info

Product

Resources

About